Prognosis Value of HIF-1α Expression in Patients with Non-small Cell Lung Cancer
Overview
Affiliations
Background: Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays a critical role in the development and progression of tumors. Various studies evaluating the prognostic value of HIF-1α in patients with lung cancer (LC) remain controversial. To comprehensively and quantitatively summarize the evidence on the effect of HIF-1α expression on the survival of patients with LC, a meta-analysis was carried out.
Material And Methods: Electronic databases were used to identify published studies before August 31st, 2013. Studies were assessed for quality using REMARK. Data were collected comparing overall survival in patients with high HIF-1α expression with those with low expression.
Results: Totally, 13 papers including 1420 patients were subjected to final analysis. The combined hazard ratio (HR) was 1.60 (95% CI: 1.14-2.25, P=0.007), suggesting that high expression of HIF-1α was an indicator of poor prognosis. Further, when stratified by LC histological type (SCLC and NSCLC), study region (Asia and Europe), cut-off values (10%), tumor stage (I-III and I-IV), antibody for IHC (H1α67 and ESEE 122), and HR estimated method (univariate/multivariate analysis), most of the results were statistically significant.
Conclusions: Taken together, this meta-analysis revealed that HIF-1α overexpression might be a predicative factor of poor prognosis for NSCLC particularly in Asia.
C/EBPβ Regulates HIF-1α-Driven Invasion of Non-Small-Cell Lung Cancer Cells.
Seo S, Lee J, Choi E, Rho S, Yoon K Biomolecules. 2025; 15(1).
PMID: 39858431 PMC: 11764306. DOI: 10.3390/biom15010036.
Hypoxia-Derived Exosomes Promote Lung Adenocarcinoma by Regulating HS3ST1-GPC4-Mediated Glycolysis.
Ji X, Zhu R, Gao C, Xie H, Gong X, Luo J Cancers (Basel). 2024; 16(4).
PMID: 38398086 PMC: 10886556. DOI: 10.3390/cancers16040695.
Li K, Niu H, Wang Y, Li R, Zhao Y, Liu C Int J Immunopathol Pharmacol. 2021; 35:20587384211048265.
PMID: 34608813 PMC: 8495526. DOI: 10.1177/20587384211048265.
Nishii K, Ohashi K, Watanabe H, Makimoto G, Nakasuka T, Higo H Oncol Lett. 2021; 22(3):639.
PMID: 34386061 PMC: 8299008. DOI: 10.3892/ol.2021.12900.
Interfering with Tumor Hypoxia for Radiotherapy Optimization.
Telarovic I, Wenger R, Pruschy M J Exp Clin Cancer Res. 2021; 40(1):197.
PMID: 34154610 PMC: 8215813. DOI: 10.1186/s13046-021-02000-x.